PREVENT-19 topline: ~90% overall efficacy
Novavax reported results from its Phase 3 study of NVX-CoV2373 (Nuvaxovid) for COVID-19 prevention on Jun 14, 2021. The linked source has what the numbers showed.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- Novavax, Inc. NVAX
- Drug
- NVX-CoV2373 (Nuvaxovid)
- For
- COVID-19 prevention
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- Jun 14, 2021
- Source note
- Phase 3 US/Mexico trial of Novavax's protein-based COVID-19 vaccine.
- Checked
- Checked by a person when it was added
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- NVAX headlines on this site
Nuvaxovid manufacturing tech transfer to Sanofi completion ($75M milestone), expected in the first half of 2027 (no exact date yet). A company milestone for Novavax (Nuvaxovid for COVID-19): a step in the program rather than a decision or a data readout.
More details
- Entry
- Nuvaxovid manufacturing tech transfer to Sanofi completion ($75M milestone) · Company milestone
- Drug
- Nuvaxovid
- For
- COVID-19
- Stage
- Commercial / partnership
- When
- H1 2027 · the company gave a window, not a day
- Source note
- Novavax Aug 6, 2026 Q2 release: manufacturing technology transfer to Sanofi expected to complete mid-2027, triggering a $75M milestone. 'mid-2027' mapped to 2027-H1 per convention (could slip into early H2).
- Checked
- Checked by a person when it was added
- Verify it
- Source: ir.novavax.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- NVAX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Novavax C. difficile vaccine clinical entry as early as 2027, expected during 2027 (no exact date yet). A company milestone for Novavax (C. difficile vaccine candidate for Clostridioides difficile infection): a step in the program rather than a decision or a data readout.
More details
- Entry
- Novavax C. difficile vaccine clinical entry as early as 2027 · Company milestone
- Drug
- C. difficile vaccine candidate
- For
- Clostridioides difficile infection
- Stage
- Preclinical / pre-IND
- When
- 2027 · the company gave a window, not a day
- Source note
- Q2 2026 release: candidate advanced into pre-IND interactions with FDA and GMP manufacturing initiated, supporting potential clinical entry as early as 2027 (hedged 'as early as').
- Checked
- Checked by a person when it was added
- Verify it
- Source: ir.novavax.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- NVAX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page